NASDAQ: PRAX

Praxis Precision Medicines (PRAX) Stock Analysis & Forecast

Nov 13 close

$328.13+3.37 (+1.0%)

Gekko Brief

AI summaryNov 9 close

Praxis reported third-quarter 2026 results this week, posting a net loss of $94.2 million against $73.9 million a year prior, attributed to higher general and administrative costs, while noting that $1.3 billion in cash and investments is expected to fund operations into 2028. The update also reaffirmed ongoing FDA reviews for relutrigine and ulixacaltamide, with PDUFA target action dates in late 2026 and early 2027 respectively. Separately, the company disclosed inducement grants of restricted stock units to new non-executive employees under its 2024 Inducement Plan.

Shares closed at $332.97, up 19.9% on the day, sitting above both the 50-day average of $291.50 and the 200-day average of $314.06. The GekkoIndex reading stands at 48, placing the stock in the Neutral zone after a five-point change of -10.3. Price remains 14.3% below Gekko Fair Value of $388.55.

Looking ahead, no confirmed earnings date is currently on the calendar, with the last report filed 6 August 2026. Smart-money activity over the past 90 days shows one Congressional buy and no sales. Seasonality data show that, from this point in the calendar, the next 20 trading days have averaged a gain of 11.1% over five years, though they rose in only 2 of those years. Analyst coverage includes 11 buy ratings and 1 hold among 12 firms, with a consensus target of $650 reflecting 95.2% upside from current levels.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Praxis Precision Medicines price vs fair value

$400.12$328.13Nov ’25May ’26Nov ’26
Close $328.13200-day averageGekko Fair Value $400.12

Praxis Precision Medicines quick facts

Market cap
$9.17B
P/E ratio
—
Forward P/E
—
EPS, TTM
−$12.82
Revenue, TTM
$7.46M
Profit margin
0%
Dividend yield
—
Beta
2.84
Volume
350,890 avg 454,235
1-year return
+78.7%
Typical daily move
±5.8%
Typical 20-day move
±15.6%
50-day average
$289.90
200-day average
$314.58
Next earnings
Feb 18 before open
Shares outstanding
27.95M
52-week range
$160.11$392.70

Praxis Precision Medicines swing-trade checklist

Praxis Precision Medicines scores 4 supportive, 2 mixed and 0 headwinds across the 6 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

4 supportive2 mixed0 headwinds

  • Trendmixed

    Averages disagree

    Close $328.13 sits between the 50-day ($289.90) and 200-day ($314.58) averages, or the averages disagree.

    See the chart
  • GekkoIndexmixed

    47.8, Neutral

    Reading 47.8 is in the Neutral zone.

    See the GekkoIndex
  • Fair valuesupportive

    18.0% below

    Price is 18% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneysupportive

    Leans bullish

    Last 90 days: Congress 1 buy / 0 sales.

    See smart money
  • Earnings risksupportive

    Reports in 95 days

    Next report Feb 18, 2027, 95 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +10.9% on average

    From this point in the calendar, the next 20 trading days averaged +10.9% over 5 years, rising in 3 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Praxis Precision Medicines stock chart and price history

Praxis Precision Medicines closed at $328.13 on Nov 13, 2026, +78.7% over the past year, inside a 52-week range of $160.11 to $392.70.

Close50-day average200-day averageVolume
Praxis Precision Medicines share price, past year, with 50-day and 200-day moving averages and volume$100$200$300$400DecJan 2026FebMarAprMayJunJulAugSepOctNov328.13

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+32.2%
3 months
−12.8%
6 months
−4.2%
1 year
+78.7%
The full PRAX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open PRAX in Gekko

Follow Praxis Precision Medicines through every session

Put PRAX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track PRAX in GekkoFree for 7 days. No credit card required.

About Praxis Precision Medicines

Praxis Precision Medicines works on drug candidates for disorders of the central nervous system linked to imbalances in neuronal signaling, and has not yet brought a product to market. Its furthest-along programs are PRAX-114, a compound acting on the GABAA receptor being tested in mid-stage trials for major depressive disorder and perimenopausal depression, and PRAX-944, a T-type calcium channel inhibitor being studied for essential tremor. It is also testing PRAX-562 for pediatric epilepsy and adult headache conditions, and developing genetic-targeted therapies for SCN2A and KCNT1 forms of epilepsy.

Its pipeline is built in part through outside partnerships rather than solely in-house work. Praxis has a licensing and cooperation agreement with RogCon, a license with Purdue Neuroscience Company, a research and licensing collaboration with Ionis Pharmaceuticals, and a joint effort with The Florey Institute to develop additional antisense therapies.

The company was founded in 2015 and is headquartered in Boston, Massachusetts. Its shares are listed on the NASDAQ under the ticker PRAX.

Listed
NASDAQ
Sector
Health technology
Industry
Pharmaceuticals: major
Website
praxismedicines.com

Praxis Precision Medicines GekkoIndex: the smart money zone

Praxis Precision Medicines’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 47.8, in the Neutral zone, down 10.4 points over five sessions.

010047.8Neutral

Down 10.4 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying51Not available
Accumulation166+1.6%+4.0%+8.7%+57.8%
Neutral (current zone)433+3.4%+7.0%+14.0%+24.7%
Distribution47+1.3%−2.0%−2.9%−1.2%
Selling5Too few readings yet

Average PRAX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the PRAX price, zone by zone.Track PRAX in Gekko

Is Praxis Precision Medicines stock overvalued? Gekko Fair Value

Praxis Precision Medicines trades 18.0% below Gekko Fair Value of $400.12, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what Praxis Precision Medicines shares are worth, recalculated every trading day.

$400.12

Gekko Fair Value, Nov 14, 2026

18.0% Undervalued

At the end of Aug 2026 the price was 34.2% below the estimate.

Gekko Fair ValueShare price, month end
$400$328Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open PRAX in Gekko

Praxis Precision Medicines insider and Congress trading

No open-market insider purchases were filed for Praxis Precision Medicines, and members of Congress disclosed 1 purchase and 0 sales, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for PRAX in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every PRAX insider filing, plotted on the chart in Gekko.Open PRAX in Gekko

Congress trades last 90 days

1trade disclosed: 1 purchase and 0 sales.

MemberTypeAmountDisclosed
Gilbert Cisneros
House, CA, purchase
Purchase$1,001 - $15,000Oct 12
traded Sep 29

From congressional disclosures, which report amounts as ranges.

Buybacks

Praxis Precision Medicines has been buying back its own shares.

Bought back, quarter ended Sep 30, 2024
$1K
As a share of market cap
0.00%

From company filings.

Praxis Precision Medicines earnings: next date and track record

Praxis Precision Medicines reports on Feb 18, 2027, before the open (95 days away), and beat the EPS estimate in 4 of its last 8 reports.

4 of 8reports beat the EPS estimate
±10.5%average move across the report
5 of 8reports followed by a gain

Share-price move across each report

+3.6%Nov ’24−48.4%Feb ’25+2.4%May ’25−11.6%Aug ’25+0.3%Nov ’25+1.9%Feb ’26−2.4%May ’26+13.0%Aug ’26

Last earnings call, Aug 6, 2026 AI summary

What they said
Praxis has two NDAs under FDA review with approvals expected within six months: ulixacaltamide for essential tremor (PDUFA January 2027) and relutrigine for SCN2A/SCN8A developmental epileptic encephalopathy (PDUFA December 27, 2026). FDA mid-cycle communications confirmed no efficacy issues and no advisory committee meetings planned for either drug. Commercial infrastructure is fully built including field force, distribution networks, and patient support programs. EMERALD study enrolled ~200 patients across 50+ genetically defined epilepsies, targeting a supplemental NDA in 2027.
Guidance
Two product launches expected within six months pending FDA approval. Relutrigine approval would qualify for a pediatric review voucher. EMERALD data could support a supplemental NDA for broader DEE indications in 2027.
ReportedEPSSurpriseRevenueSurpriseMove
Aug 6, 2026−$2.87
est −$3.67
+21.8%—
est $1.25M
—+13.0%
May 7, 2026−$3.20
est −$3.68
+13.0%—
est $100K
—−2.4%
Feb 19, 2026−$3.50
est −$3.13
−11.8%—
est $67K
—+1.9%
Nov 5, 2025−$3.36
est −$3.45
+2.6%—
est $256K
—+0.3%
Aug 4, 2025−$3.31
est −$3.36
+1.5%—
est $59K
—−11.6%
May 2, 2025−$3.29
est −$3.21
−2.5%—
est $199K
—+2.4%
Feb 28, 2025−$2.94
est −$2.82
−4.3%$7.46M
est $298K
+2,405.4%−48.4%
Nov 6, 2024−$2.75
est −$1.95
−41.0%——+3.6%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Praxis Precision Medicines stock forecast and analyst price targets

Analysts’ average 12-month price target for Praxis Precision Medicines is $661.75, +101.7% from the last close, from 13 firms rating the stock in the last 90 days.

$661.75consensus 12-month target, +101.7% from the last close
Low $343High $1,201
Buy12
Hold1
Sell0

Each firm’s latest rating in the last 90 days: 13 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 13Piper SandlerBuy, maintained$1,200+265.7%
Nov 13H.C. WainwrightBuy, maintained$1,201+266.0%
Nov 12RBC CapitalBuy, maintained$478+45.7%
Nov 10OppenheimerBuy, reiterated$650+98.1%
Nov 10JonesTradingBuy, reiterated$534+62.7%
+14.0%average 20-day move after past Neutral readings
+10.9%average move over the next 20 trading days in the last 5 years
±5.8%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Praxis Precision Medicines seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Praxis Precision Medicines averaged +10.9% across the last 5 years, rising in 3 of them.

Next 20 trading days, by year

−5.8%2021+3.3%2022+21.7%2023−8.7%2024+48.3%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−4.5%1 of 5
Next 10 trading days+2.4%2 of 5
Next 15 trading days+11.3%2 of 5
Next 20 trading days+10.9%3 of 5
Next 30 trading days+22.3%3 of 5

For scale, PRAX’s typical 20-trading-day move in either direction is about 15.6%.

Praxis Precision Medicines market cap and key statistics

Praxis Precision Medicines’s market cap is $9.17B and revenue of $7.46M over the last twelve months.

Valuation

Market cap
$9.17B
EPS, TTM
−$12.82
Gekko Fair Value
$400.12

Trading

Volume
350,890
Avg volume, 20 days
454,235
52-week high
$392.70
52-week low
$160.11
Shares outstanding
27.95M

Financials

Revenue, TTM
$7.46M
Profit margin
0%
Return on equity
-44.8%
Quarterly earnings growth, YoY
0.0%

Risk and income

Beta
2.84
Typical daily move
±5.8%
Typical 20-day move
±15.6%

Praxis Precision Medicines peers

Praxis Precision Medicines’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
LLYEli Lilly+1.0%Neutral24.0% above
JNJJohnson & Johnson+0.3%Neutral4.4% above
ABBVAbbVie−0.5%Neutral23.7% above
MRKMerck+0.3%Neutral8.2% below
AZNAstraZeneca−0.2%Neutral34.6% below
PFEPfizer−0.1%Accumulation8.9% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Pharmaceuticals: major

Praxis Precision Medicines stock FAQ

What is Praxis Precision Medicines’s market cap?

Praxis Precision Medicines’s market cap is $9.17B at the Nov 13, 2026 close of $328.13, with 27.95M shares outstanding.

What is the Praxis Precision Medicines stock forecast?

The consensus analyst 12-month price target for Praxis Precision Medicines is $661.75, +101.7% from the last close. Of the 13 firms that rated the stock in the last 90 days, 12 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Praxis Precision Medicines stock overvalued or undervalued?

On Gekko’s estimate Praxis Precision Medicines is undervalued: the Nov 13, 2026 close of $328.13 is 18.0% below Gekko Fair Value of $400.12. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Praxis Precision Medicines report earnings next?

Praxis Precision Medicines is expected to report on Feb 18, 2027, before the market opens (95 days away). Analysts expect earnings of −$4.08 per share on revenue of $377K. Praxis Precision Medicines beat the earnings estimate in 4 of its last 8 reports, moving 10.5% on average across the report.

What is Praxis Precision Medicines’s 52-week high and low?

Praxis Precision Medicines’s 52-week high is $392.70 and its 52-week low is $160.11; it closed at $328.13 on Nov 13, 2026, +78.7% over the past year.

Is Praxis Precision Medicines stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (fair value, smart money, earnings risk and seasonality), 2 as mixed (trend and gekkoindex). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Praxis Precision Medicines the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.